Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Leveraging an innovative discovery platform, Curileum Discovery is developing an approach based on stem cell drugs that has the potential to cure a wide range of gastrointestinal disorders.
By translating academic innovation and partnering with big pharma, the University of Dundee’s Drug Discovery Unit (DDU) is developing novel therapeutic targets to a stage where they can be smoothly transitioned across to the pharmaceutical industry.
Anatabine citrate, a cholinergic small molecule in development at Rock Creek Pharmaceuticals, offers a distinct alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologics for the treatment of chronic and acute inflammatory diseases. The company is looking to partner for a phase 2 trial in psoriasis.
Combining its heritage in innovation with capabilities in clinical translational medicine, Ulster University has created a pipeline of promising licensing opportunities that target a number of therapeutic areas.
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, is a first-of-its-kind international center for research on and development of microbial and mammalian-cell–based production platforms.
Recognizing that even broad, multidisciplinary teams need external support, GSK has formed over 115 partnerships to help develop vaccines for the future.
The National Institute of Allergy and Infectious Diseases’ (NIAID) Technology Transfer and Intellectual Property Office (TTIPO) has been instrumental in advancing innovation, continuously building on the institute’s record of scientific excellence with its partners.
Motif Bio’s iclaprim shows rapid bactericidal activity and low propensity for induction of resistance and is in late-stage clinical testing for acute bacterial skin and skin structure infections.
By mimicking the way viruses bind to host cells, NanoViricides is developing unique nanomedicines that are able to trick, trap and destroy these pathogens.
New biotech company Lantern Pharma is leading a wave of innovation in cancer treatment by bringing the best therapies to the patients who are most likely to respond.
Through its nimble Office of Therapeutics Alliances, NYU Langone Medical Center is harnessing the therapeutic potential of its world-class research by partnering with external experts in commercial drug discovery and development to advance the next generation of medical therapies and diagnostics.
The Center for Research and Advanced Studies (Cinvestav) is a national leader in scientific research, technology development and the formation of highly educated professionals in Mexico. Cinvestav is now expanding its reach globally with a nanoparticle-based therapy for Parkinson’s disease that represents an opportunity for international partnerships.
CALYM is a nonprofit research institute that offers a unique R&D approach in lymphoma treatments and diagnostics, spanning from new target identification to large international phase 3 clinical trials.
